Implications of the Cancer Stem-cell Hypothesis for Breast Cancer Prevention and Therapy

Overview

Journal J Clin Oncol

Specialty Oncology

Date 2008 Jun 10

PMID 18539959

Citations 191

Authors

Madhuri Kakarala

Max S Wicha

Affiliations

Soon will be listed here.

Abstract

Recent research in breast biology has provided support for the cancer stem-cell hypothesis. Two important components of this hypothesis are that tumors originate in mammary stem or progenitor cells as a result of dysregulation of the normally tightly regulated process of self-renewal. As a result, tumors contain and are driven by a cellular subcomponent that retains key stem-cell properties including self-renewal, which drives tumorigenesis and differentiation that contributes to cellular heterogeneity. Advances in stem-cell technology have led to the identification of stem cells in normal and malignant breast tissue. The study of these stem cells has helped to elucidate the origin of the molecular complexity of human breast cancer. The cancer stem-cell hypothesis has important implications for early detection, prevention, and treatment of breast cancer. Both hereditary and sporadic breast cancers may develop through dysregulation of stem-cell self-renewal pathways. These aberrant stem cells may provide targets for the development of cancer prevention strategies. Furthermore, because breast cancer stem cells may be highly resistant to radiation and chemotherapy, the development of more effective therapies for this disease may require the effective targeting of this cell population.

Citing Articles

Epigenetic regulatory protein chromobox family regulates multiple signalling pathways and mechanisms in cancer.

Su W, Wang W, Zhang G, Yang L Clin Epigenetics. 2025; 17(1):48.

PMID: 40083014 PMC: 11907984. DOI: 10.1186/s13148-025-01852-w.

Mechanism of action of genistein on breast cancer and differential effects of different age stages.

Xiang Z, Ma B, Pei X, Wang W, Gong W Pharm Biol. 2025; 63(1):141-155.

PMID: 39996512 PMC: 11864014. DOI: 10.1080/13880209.2025.2469607.

Primary tumor resection in metastatic breast cancer from an oligometastatic perspective: A systematic review and meta-analysis.

Wu C, Li X, Liu S, Yao L, He T, Wang Y iScience. 2024; 27(12):111224.

PMID: 39618499 PMC: 11607599. DOI: 10.1016/j.isci.2024.111224.

Anti-Tumor Immunity to Patient-Derived Breast Cancer Cells by Vaccination with Interferon-Alpha-Conditioned Dendritic Cells (IFN-DC).

Lapenta C, Santini S, Antonacci C, Donati S, Cecchetti S, Frittelli P Vaccines (Basel). 2024; 12(9).

PMID: 39340087 PMC: 11435915. DOI: 10.3390/vaccines12091058.

B3GNT5 is a novel marker correlated with malignant phenotype and poor outcome in pancreatic cancer.

Yao W, Wang Y, Zhang X, Lin Y iScience. 2024; 27(10):110889.

PMID: 39319269 PMC: 11421285. DOI: 10.1016/j.isci.2024.110889.

References

Li Y, Bu G . LRP5/6 in Wnt signaling and tumorigenesis. Future Oncol. 2006; 1(5):673-81. DOI: 10.2217/14796694.1.5.673. View

Saal L, Gruvberger-Saal S, Persson C, Lovgren K, Jumppanen M, Staaf J . Recurrent gross mutations of the PTEN tumor suppressor gene in breast cancers with deficient DSB repair. Nat Genet. 2007; 40(1):102-7. PMC: 3018354. DOI: 10.1038/ng.2007.39. View

Stingl J, Eirew P, Ricketson I, Shackleton M, Vaillant F, Choi D . Purification and unique properties of mammary epithelial stem cells. Nature. 2006; 439(7079):993-7. DOI: 10.1038/nature04496. View

Ginestier C, Hur M, Charafe-Jauffret E, Monville F, Dutcher J, Brown M . ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell. 2008; 1(5):555-67. PMC: 2423808. DOI: 10.1016/j.stem.2007.08.014. View

Tang C, Chua C, Ang B . Insights into the cancer stem cell model of glioma tumorigenesis. Ann Acad Med Singap. 2007; 36(5):352-7. View

Pahlke G, Ngiewih Y, Kern M, Jakobs S, Marko D, Eisenbrand G . Impact of quercetin and EGCG on key elements of the Wnt pathway in human colon carcinoma cells. J Agric Food Chem. 2006; 54(19):7075-82. DOI: 10.1021/jf0612530. View

Savarese T, Strohsnitter W, Low H, Liu Q, Baik I, Okulicz W . Correlation of umbilical cord blood hormones and growth factors with stem cell potential: implications for the prenatal origin of breast cancer hypothesis. Breast Cancer Res. 2007; 9(3):R29. PMC: 1929091. DOI: 10.1186/bcr1674. View

Jenkins P . Acromegaly and cancer. Horm Res. 2005; 62 Suppl 1:108-15. DOI: 10.1159/000080768. View

Nickoloff B, Osborne B, Miele L . Notch signaling as a therapeutic target in cancer: a new approach to the development of cell fate modifying agents. Oncogene. 2003; 22(42):6598-608. DOI: 10.1038/sj.onc.1206758. View

10.

Martinez-Climent J, Andreu E, Prosper F . Somatic stem cells and the origin of cancer. Clin Transl Oncol. 2006; 8(9):647-63. DOI: 10.1007/s12094-006-0035-7. View

11.

Foulkes W . BRCA1 functions as a breast stem cell regulator. J Med Genet. 2004; 41(1):1-5. PMC: 1757264. DOI: 10.1136/jmg.2003.013805. View

12.

Miele L, Golde T, Osborne B . Notch signaling in cancer. Curr Mol Med. 2006; 6(8):905-18. DOI: 10.2174/156652406779010830. View

13.

Sakariassen P, Immervoll H, Chekenya M . Cancer stem cells as mediators of treatment resistance in brain tumors: status and controversies. Neoplasia. 2007; 9(11):882-92. PMC: 2077879. DOI: 10.1593/neo.07658. View

14.

Panigrahi A, Pinder S, Chan S, Paish E, Robertson J, Ellis I . The role of PTEN and its signalling pathways, including AKT, in breast cancer; an assessment of relationships with other prognostic factors and with outcome. J Pathol. 2004; 204(1):93-100. DOI: 10.1002/path.1611. View

15.

Yu F, Yao H, Zhu P, Zhang X, Pan Q, Gong C . let-7 regulates self renewal and tumorigenicity of breast cancer cells. Cell. 2007; 131(6):1109-23. DOI: 10.1016/j.cell.2007.10.054. View

16.

Dontu G, Liu S, Wicha M . Stem cells in mammary development and carcinogenesis: implications for prevention and treatment. Stem Cell Rev. 2006; 1(3):207-13. DOI: 10.1385/SCR:1:3:207. View

17.

Patocs A, Zhang L, Xu Y, Weber F, Caldes T, Mutter G . Breast-cancer stromal cells with TP53 mutations and nodal metastases. N Engl J Med. 2007; 357(25):2543-51. DOI: 10.1056/NEJMoa071825. View

18.

Slamon D, Pegram M . Rationale for trastuzumab (Herceptin) in adjuvant breast cancer trials. Semin Oncol. 2001; 28(1 Suppl 3):13-9. DOI: 10.1016/s0093-7754(01)90188-5. View

19.

Heron M . Deaths: leading causes for 2004. Natl Vital Stat Rep. 2007; 56(5):1-95. View

20.

Dontu G, Wicha M . Survival of mammary stem cells in suspension culture: implications for stem cell biology and neoplasia. J Mammary Gland Biol Neoplasia. 2005; 10(1):75-86. DOI: 10.1007/s10911-005-2542-5. View